- More Evidence Bolsters the Oral Herpes and Alzheimer’s Link
- Health Advocates Are Unhappy with FDA Guidance on Lead Levels in Baby Food
- FDA Calls for Better Accuracy of Pulse Oximeters in People of Color
- Fluoride May Be Linked to Decreased IQ, Says “Limited Data,” Hard-to-Interpret Study
- First U.S. Death From Bird Flu Reported in Louisiana
- Blood Test May Help Predict How Long Immunity Lasts
- DoxyPEP Lowers Rate of Sexually Transmitted Infections (STIs), Data Suggests
- Multilingual Children with Autism Show Improved Cognitive Function
- Access to Medical Test Results Is Confusing, Anxiety-Provoking
- Caregivers Face Mental, Physical Health Risks
Blood Test for Yeast Infections Approved
The first blood test to detect five strains of yeast that cause rare blood infections in people with weakened immune systems has been approved by the U.S. Food and Drug Administration.
The five types of yeast pathogen detected by the T2Candida test can cause deadly bloodstream infections if not treated quickly, the FDA said in a news release. People at greatest risk of the infections include those being treated for cancer, those who have been given immune system-suppressing drugs after an organ transplant and severely ill people in intensive care.
Results from the new test are available in three to five hours, compared to six days or longer from traditional methods, the FDA said. The faster results may allow doctors to begin treatment sooner.
But since false positives are possible from the new test, results should be confirmed by blood culture, the agency advised.
The new test was evaluated in clinical studies of about 1,800 people. Negative results were correctly identified nearly 100 percent of the time, and the yeast organism involved was correctly identified in 84 percent to 96 percent of positive specimens, the FDA said.
The T2Candida test is produced by T2 Biosystems, based in Lexington, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.